fluoxetine has been researched along with pramipexole in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Corrigan, MH; Denahan, AQ; Evans, DL; Ragual, RJ; Wright, CE | 1 |
| Berghauzen-Maciejewska, K; Dziubina, A; Głowacka, U; Kolasiewicz, W; Kuter, K; Ossowska, K; Wardas, J | 1 |
| Deng, CM; Gao, YY; Li, Y; Mu, YL; Ou, BC; So, JH; Tan, ZB; Tang, M; Wang, YQ; Zhang, LQ; Zhu, ZR | 1 |
1 review(s) available for fluoxetine and pramipexole
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for fluoxetine and pramipexole
| Article | Year |
|---|---|
Comparison of pramipexole, fluoxetine, and placebo in patients with major depression.
Topics: Adult; Benzothiazoles; Depressive Disorder, Major; Dopamine Agonists; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Personality Assessment; Pramipexole; Selective Serotonin Reuptake Inhibitors; Thiazoles | 2000 |
4 other study(ies) available for fluoxetine and pramipexole
| Article | Year |
|---|---|
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Pramipexole but not imipramine or fluoxetine reverses the "depressive-like" behaviour in a rat model of preclinical stages of Parkinson's disease.
Topics: Animals; Antidepressive Agents; Benzothiazoles; Depression; Disease Models, Animal; Dopamine Agonists; Fluoxetine; Imipramine; Male; Motor Activity; Oxidopamine; Parkinson Disease; Pramipexole; Rats; Rats, Wistar; Swimming; Treatment Outcome | 2014 |
Dopamine D2/D3 but not dopamine D1 receptors are involved in the rapid antidepressant-like effects of ketamine in the forced swim test.
Topics: Animals; Antidepressive Agents; Benzazepines; Benzothiazoles; Dizocilpine Maleate; Fluoxetine; Haloperidol; Ketamine; Male; Mice; Motor Activity; Pramipexole; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Dopamine D3; Receptors, N-Methyl-D-Aspartate; Swimming | 2015 |